J&J Bets $20 Million on DNA Tool to Battle Infectious Bacteria
Photographer: Science Photo Library via Getty Images
This article is for subscribers only.
Johnson & Johnson will invest $20 million, and as much as $798 million in future payments, in Locus Bioscience Inc., a startup using the genetic technology Crispr to battle antibiotic resistance.